271 related articles for article (PubMed ID: 7630638)
1. Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain.
Nguyen H; Mustafa A; Hiscott J; Lin R
Oncogene; 1995 Aug; 11(3):537-44. PubMed ID: 7630638
[TBL] [Abstract][Full Text] [Related]
2. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo.
Kröger A; Dallügge A; Kirchhoff S; Hauser H
Oncogene; 2003 Feb; 22(7):1045-56. PubMed ID: 12592391
[TBL] [Abstract][Full Text] [Related]
3. Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression.
Tan RS; Taniguchi T; Harada H
Cancer Res; 1996 May; 56(10):2417-21. PubMed ID: 8625321
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic transcription factor IRF-2 possesses a transcriptional repression and a latent activation domain.
Yamamoto H; Lamphier MS; Fujita T; Taniguchi T; Harada H
Oncogene; 1994 May; 9(5):1423-8. PubMed ID: 8152803
[TBL] [Abstract][Full Text] [Related]
5. The role of the interferon regulatory factors, IRF-1 and IRF-2, in LPS-induced cyclooxygenase-2 (COX-2) expression in vivo and in vitro.
Zhang S; Thomas K; Blanco JC; Salkowski CA; Vogel SN
J Endotoxin Res; 2002; 8(5):379-88. PubMed ID: 12537697
[TBL] [Abstract][Full Text] [Related]
6. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.
Matsuyama T; Kimura T; Kitagawa M; Pfeffer K; Kawakami T; Watanabe N; Kündig TM; Amakawa R; Kishihara K; Wakeham A
Cell; 1993 Oct; 75(1):83-97. PubMed ID: 8402903
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma regulation of the human mimecan promoter.
Tasheva ES; Conrad GW
Mol Vis; 2003 Jun; 9():277-87. PubMed ID: 12835654
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity.
Kondo T; Minamino N; Nagamura-Inoue T; Matsumoto M; Taniguchi T; Tanaka N
Oncogene; 1997 Sep; 15(11):1275-81. PubMed ID: 9315094
[TBL] [Abstract][Full Text] [Related]
9. The interferon regulatory factors 1 and 2 bind to a segment of the human c-myb first intron: possible role in the regulation of c-myb expression.
Manzella L; Gualdi R; Perrotti D; Nicolaides NC; Girlando G; Giuffrida MA; Messina A; Calabretta B
Exp Cell Res; 2000 Apr; 256(1):248-56. PubMed ID: 10739671
[TBL] [Abstract][Full Text] [Related]
10. Conserved high-affinity NF-kappa B binding site in the interferon regulatory factor-1 promoter is not occupied by NF-kappa B in vivo and is transcriptionally inactive.
Rein T; Schreck R; Willenbrink W; Neubert WJ; Zorbas H; Bäuerle PA
J Inflamm; 1995; 45(4):269-82. PubMed ID: 8867671
[TBL] [Abstract][Full Text] [Related]
11. Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation.
Nguyen H; Teskey L; Lin R; Hiscott J
Oncogene; 1999 Sep; 18(39):5455-63. PubMed ID: 10498899
[TBL] [Abstract][Full Text] [Related]
12. Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors.
Meraro D; Hashmueli S; Koren B; Azriel A; Oumard A; Kirchhoff S; Hauser H; Nagulapalli S; Atchison ML; Levi BZ
J Immunol; 1999 Dec; 163(12):6468-78. PubMed ID: 10586038
[TBL] [Abstract][Full Text] [Related]
13. Induction of transcription factor interferon regulatory factor-1 by interferon-gamma (IFN gamma) and tumor necrosis factor-alpha (TNF alpha) in FRTL-5 cells.
Mori K; Stone S; Khaodhiar L; Braverman LE; DeVito WJ
J Cell Biochem; 1999 Aug; 74(2):211-9. PubMed ID: 10404391
[TBL] [Abstract][Full Text] [Related]
14. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice.
Yim JH; Wu SJ; Casey MJ; Norton JA; Doherty GM
J Immunol; 1997 Feb; 158(3):1284-92. PubMed ID: 9013971
[TBL] [Abstract][Full Text] [Related]
15. A dominant negative mutant of an IFN regulatory factor family protein inhibits both type I and type II IFN-stimulated gene expression and antiproliferative activity of IFNs.
Thornton AM; Ogryzko VV; Dent A; Sharf R; Levi BZ; Kanno Y; Staudt LM; Howard BH; Ozato K
J Immunol; 1996 Dec; 157(11):5145-54. PubMed ID: 8943426
[TBL] [Abstract][Full Text] [Related]
16. Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins.
Nguyen H; Lin R; Hiscott J
Oncogene; 1997 Sep; 15(12):1425-35. PubMed ID: 9333018
[TBL] [Abstract][Full Text] [Related]
17. [Cellular responses by cytokines--gene regulation in the IFN system].
Taniguchi T
Rinsho Ketsueki; 1991 Apr; 32(4):301-6. PubMed ID: 1712401
[TBL] [Abstract][Full Text] [Related]
18. Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2.
Vaughan PS; Aziz F; van Wijnen AJ; Wu S; Harada H; Taniguchi T; Soprano KJ; Stein JL; Stein GS
Nature; 1995 Sep; 377(6547):362-5. PubMed ID: 7566094
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of interferon (IFN) regulatory factors 1 and 2. Effects on the induction of IFN-beta gene expression.
Lin R; Mustafa A; Nguyen H; Gewert D; Hiscott J
J Biol Chem; 1994 Jul; 269(26):17542-9. PubMed ID: 8021262
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of interferon beta gene transcription in vitro by purified NF-kappa B and a novel TH protein.
Cohen L; Lacoste J; Parniak M; Daigneault L; Skup D; Hiscott J
Cell Growth Differ; 1991 Jul; 2(7):323-33. PubMed ID: 1782151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
